Which Drugs Are Use For Destroy the Sex? Which Drugs Are Use For Destroy the Sex?/Goserelin is a synthetic long-acting agonist of the GONADOTROPIN-RELEASING HORMONE and is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer. Goserelin is a parenterally administered, gonadotropin-releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer. Goserelin has been associated with a modest rate of serum enzyme elevations during therapy but has not been convincingly linked to instances of clinically apparent acute liver injury. Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04) Goserelin Acetate is the acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04) Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. Mechanism of Action Goserelin is a synthetic decapeptide analog of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in a biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Zoladex is a synthetic decapeptide analog of LHRH. Zoladex acts as a potent inhibitor of pituitary gonadotropin secretion when administered in a biodegradable formulation. Following initial administration, ZOLADEX causes an initial increase in serum-luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels with subsequent increases in serum levels of testosterone. Chronic administration of Zoladex leads to sustained suppression of pituitary gonadotropins, and serum levels of testosterone consequently fall into the range normally seen in surgically castrated men approximately 21 days after initiation of therapy. This leads to accessory sex organ regression. In animal and in in vitro studies, administration of goserelin resulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-induced rat mammary tumor and Dunning R3327 prostate tumor. In clinical trials using Zoladex 3.6 mg with follow-up of more than 2 years, suppression of serum testosterone to castrate levels has been maintained for the duration of therapy. Indications Goserelin is indicated for: – Use in combination with flutamide for the management of locally confined carcinoma of the prostate – Palliative treatment of advanced carcinoma of the prostate – The management of endometriosis – Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding – Use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women Goserelin is a parenterally administered, gonadotropin-releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer. Use in combination with flutamide for the management of locally confined carcinoma of the prostate Palliative treatment of advanced carcinoma of the prostate The management of endometriosis Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding Use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women Abnormal Uterine Bleeding Advanced Breast Cancer Endometriosis Advanced carcinoma of the prostate Stage T2b carcinoma of the prostate Stage T4 carcinoma of the prostate Goserelin is a medication that is used to suppress the production of sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin-releasing hormone agonist (GnRH agonist). Goserelin acetate is used for the palliative treatment of advanced prostate cancer. Therapy with a GnRH agonist (e.g., goserelin) currently is considered one of several first-line options for hormonal therapy in patients with prostate cancer Goserelin is used for the palliative treatment of endometriosis. The manufacturer states that experience with goserelin in the management of this condition has been limited to women 18 years of age and older who received consecutive therapy … with the drug for 6 months. Goserelin, like other GnRH analogs, produces a reversible hypoestrogenic state, which is thought to be principally responsible for the beneficial effects observed in endometriosis. A 6-month course of goserelin therapy can provide symptomatic (e.g., pain) relief and a reduction in endometriotic lesions; some degree of improvement has persisted in many patients for at least 6 months following completion of therapy. Substantial improvement of clinical symptoms usually occurs within 4 weeks of initiation of goserelin therapy. Goserelin is used in the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women. In a multicenter, randomized, controlled clinical trial in women with estrogen- or progesterone-receptor-positive breast cancer, goserelin therapy or oophorectomy was associated with objective response rates (complete or partial responses) of 22-31 or 12-27%, time to treatment failure of 6-6.7 or 4-5.5 months, and median survival time of 33.2 or 33.6 months, respectively. In addition, subjective response, characterized by relief of pain and improved performance status, was reported in 48 or 50% of women receiving goserelin or undergoing surgery, respectively. Goserelin is used as an endometrial-thinning agent prior to endometrial ablation procedures for the treatment of dysfunctional uterine bleeding. In women with dysfunctional uterine bleeding, administration of goserelin (two doses of goserelin (3.6 mg each) given 4 weeks apart) prior to surgery suppressed endometrial growth, reduced uterine size and endometrial thickness, and facilitated surgical ablation. Use in Cancer Goserelin acetate is approved to treat: Breast cancer is advanced. It is used as palliative treatment in premenopausal and perimenopausal women. Prostate cancer. It is used with flutamide and radiation therapy in localized prostate cancer. It is also used as palliative treatment in advanced prostate cancer. Goserelin acetate is also being studied in conditions related to cancer. Contraindications Goserelin is contraindicated in patients with hypersensitivity to goserelin, GnRH, or with Gonadotropin-Releasing Hormone (GnRH) Analogs hypersensitivity; anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported. cancer metastasis to bone diabetes high cholesterol low amount of magnesium in the blood low amount of calcium in the blood high amount of calcium in the blood low amount of potassium in the blood overweight high blood pressure a heart attack prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth a stroke pregnancy obstruction of any part of the urinary tract tobacco smoking Dosage Prostate Cancer For the palliative treatment of advanced carcinoma of the prostate: 3.6 mg or 10.8 mg subcutaneously into the upper abdominal wall once The 3.6 mg dosage may be repeated every 28 days. The 10.8 mg dosage may be repeated every 12 weeks. Intended for long-term administration unless clinically inappropriate. Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males: SubQ: Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant OR 28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy) In combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should start 8 weeks prior to radiation therapy and continue during radiation. For the palliative treatment of advanced carcinoma of the prostate. Endometriosis 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days. The recommended duration of therapy is 6 months. For the management of endometriosis, including pain relief and reduction of endometriotic lesions. Breast Cancer–Palliative For use in the palliative treatment of advanced breast cancer: 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days Intended for long-term administration unless clinically inappropriate. For the palliative treatment of advanced breast cancer in pre-and perimenopausal women Dose for Bleeding 1 or 2 of the 3.6 mg subcutaneous depot injections (with each depot given 4 weeks apart). When 1 depot is administered, surgery should be performed at 4 weeks. When 2 depots are administered, surgery should be performed within 2 to 4 weeks following the administration of the second depot. Administration Technique The proper method of administration of ZOLADEX is described in the instructions that follow. Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare an area of the anterior abdominal wall below the navel line with an alcohol swab. NOTE: Caution should be taken while injecting ZOLADEX into the anterior abdominal wall due to the proximity of the underlying inferior epigastric artery and its branches. Examine the foil pouch and syringe for damage. Remove the syringe from the opened foil pouch and hold the syringe at a slight angle to the light. Check that at least part of the ZOLADEX implant is visible. Grasp the red plastic safety tab and pull away from the syringe, and discard. Remove the needle cover. Unlike liquid injections, there is no need to remove air bubbles as attempts to do so may displace the ZOLADEX implant. Holding the syringe around the protective sleeve, using an aseptic technique, pinch the skin of the patient’s anterior abdominal wall below the navel line. With the bevel of the needle facing up, insert the needle at a 30 to 45-degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient’s skin. NOTE: The ZOLADEX syringe cannot be used for aspiration. If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and inject it with a new syringe elsewhere. Monitor patients for signs or symptoms of abdominal hemorrhage. Use extra care when administering ZOLADEX to patients with a low BMI and/or to patients receiving full-dose anticoagulation. Do not penetrate into muscle or peritoneum. To administer the ZOLADEX implant and to activate the protective sleeve, grasp the barrel at the finger grip and depress the plunger until you cannot depress it any further. If the plunger is not depressed fully, the protective sleeve will NOT activate. When the protective sleeve ‘clicks’, the protective sleeve will automatically begin to slide to cover the needle. NOTE: The needle does not retract. Withdraw the needle and allow the protective sleeve to slide and cover the needle. Dispose of the syringe in an approved sharps collector. Side Effects The Most Common headache hot flashes (a sudden wave of mild or intense body heat) sweating sudden reddening of the face, neck, or upper chest lack of energy loss of appetite breast pain or change in breast size in women decreased sexual desire or ability painful sexual intercourse vaginal discharge, dryness, or itching menstruation (periods) swelling of the hands, feet, ankles, or lower legs depression nervousness unable to control emotions and frequent mood changes difficulty falling asleep or staying asleep pain, itching, swelling, or redness at the place where the implant was inserted hives rash itching difficulty breathing or swallowing chest pain pain in the arms, back, neck, or jaw unusual weight gain slow or difficult speech dizziness or fainting weakness or numbness of an arm or leg bone pain not able to move legs painful or difficult urination frequent urination extreme thirst weakness blurred vision dry mouth nausea vomiting breath that smells fruity decreased consciousness More Common Fast or irregular heartbeat Bone, muscle, or joint pain changes in the skin color of the face fainting fast or irregular breathing numbness or tingling of the hands or feet puffiness or swelling of the eyelids or around the eyes skin rash, hives, or itching sudden, severe decrease in blood pressure and collapse tightness in the chest troubled breathing pain, bruising, swelling, redness, oozing, or bleeding where the implant was injected; dizziness, trouble breathing, feeling light-headed (like you might pass out); high blood sugar – increased thirst, increased urination, dry mouth, fruity breath odor; high calcium levels – confusion, tiredness, nausea, vomiting, loss of appetite, constipation, increased thirst or urination, weight loss; heart attack symptoms – chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating; or signs of a blood clot – sudden numbness or weakness on one side of the body, chest pain, problems with vision or speech, pain or swelling in one leg. RARE Anxiety deepening of voice increased hair growth mental depression mood changes Pain in the chest pain in the groin or legs (especially in the calves of the legs) Sudden sweating and feelings of warmth (also called hot flashes) Blurred vision burning, itching, redness, or swelling at the place of injection decreased interest in sexual intercourse dizziness headache nausea or vomiting swelling and increased tenderness of the breasts swelling of the feet or lower legs trouble sleeping weight gain Light, irregular vaginal bleeding stopping of menstrual periods Burning, dryness, or itching of the vagina pelvic pain Bone pain constipation decreased size of the testicles inability to have or keep an erection Drug Interactions Abacavir Goserelin may decrease the excretion rate of Abacavir which could result in a higher serum level. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin. Aceclofenac Aceclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Goserelin which could result in a higher serum level. Acetaminophen Goserelin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Aclidinium Goserelin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Goserelin. Acyclovir Acyclovir may decrease the excretion rate of Goserelin which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Goserelin which could result in a higher serum level. Adenosine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Goserelin. Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin. Albutrepenonacog Goserelin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. Aldesleukin Goserelin may decrease the excretion rate of Aldesleukin which could result in a higher serum level. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Goserelin. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Goserelin. Allopurinol Goserelin may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almasilate Goserelin may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Goserelin may decrease the excretion rate of Almotriptan which could result in a higher serum level. Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin. Alprazolam Goserelin may decrease the excretion rate of Alprazolam which could result in a higher serum level. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Goserelin. Amifampridine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amifampridine. Amikacin Goserelin may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride Amiloride may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone Aminophenazone may decrease the excretion rate of Goserelin which could result in a higher serum level. Amiodarone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amisulpride. Amitriptyline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amitriptyline. Ammonium Goserelin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Goserelin. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Goserelin. Amoxicillin Goserelin may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Amphetamine Goserelin may decrease the excretion rate of Amphetamine which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level. Ampicillin Goserelin may decrease the excretion rate of Ampicillin which could result in a higher serum level. Amrinone Goserelin may decrease the excretion rate of Amrinone which could result in a higher serum level. Anagrelide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Anagrelide. Ancestim Goserelin may decrease the excretion rate of Ancestim which could result in a higher serum level. Antazoline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Antazoline. Antihemophilic Goserelin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antipyrine Antipyrine may decrease the excretion rate of Goserelin which could result in a higher serum level. Antithrombin III Goserelin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antrafenine Antrafenine may decrease the excretion rate of Goserelin which could result in a higher serum level. Apalutamide Goserelin may decrease the excretion rate of Apalutamide which could result in a higher serum level. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Goserelin. Apremilast Goserelin may decrease the excretion rate of Apremilast which could result in a higher serum level. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Goserelin. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Goserelin. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Goserelin is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Articaine. Asenapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Asenapine. Astemizole The risk or severity of QTc prolongation can be increased when Goserelin is combined with Astemizole. Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Goserelin. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Goserelin. Atropine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Atropine. Auranofin Goserelin may decrease the excretion rate of Auranofin which could result in a higher serum level. Aurothioglucose Goserelin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Azacitidine Goserelin may decrease the excretion rate of Azacitidine which could result in a higher serum level. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Goserelin. Azathioprine Goserelin may decrease the excretion rate of Azathioprine which could result in a higher serum level. Azelaic acid Goserelin may decrease the excretion rate of Azelaic acid which could result in a higher serum level. Azithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Azithromycin. Aztreonam Goserelin may decrease the excretion rate of Aztreonam which could result in a higher serum level. Bacitracin Bacitracin may decrease the excretion rate of Goserelin which could result in a higher serum level. Baclofen Goserelin may decrease the excretion rate of Baclofen which could result in a higher serum level. Balsalazide Balsalazide may decrease the excretion rate of Goserelin which could result in a higher serum level. Baricitinib Goserelin may decrease the excretion rate of Baricitinib which could result in a higher serum level. Bedaquiline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bedaquiline. Bendroflumethiaz Bendroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Goserelin which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Benserazide Goserelin may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Goserelin. Benznidazole Goserelin may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzocaine. Benzthiazide Benzthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Goserelin which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzyl alcohol. Bepotastine Goserelin may decrease the excretion rate of Bepotastine which could result in a higher serum level. Bepridil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bepridil. Berotralstat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Berotralstat. Bicisate Goserelin may decrease the excretion rate of Bicisate which could result in a higher serum level. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Goserelin. Bismuth Goserelin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol Goserelin may decrease the excretion rate of Bisoprolol which could result in a higher serum level. Bisoxatin Goserelin may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bleomycin Goserelin may decrease the excretion rate of Bleomycin which could result in a higher serum level. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Goserelin. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Goserelin. Brivaracetam Goserelin may decrease the excretion rate of Brivaracetam which could result in a higher serum level. Bromazepam Goserelin may decrease the excretion rate of Bromazepam which could result in a higher serum level. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin. Bromotheophylline Bromotheophylline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Goserelin. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Goserelin. Budesonide Goserelin may decrease the excretion rate of Budesonide which could result in a higher serum level. Bumadizone Bumadizone may decrease the excretion rate of Goserelin which could result in a higher serum level. Bumetanide Bumetanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Bupivacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Bupivacaine. Bupropion Goserelin may decrease the excretion rate of Bupropion which could result in a higher serum level. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Goserelin. Buspirone Goserelin may decrease the excretion rate of Buspirone which could result in a higher serum level. Butabarbital Goserelin may decrease the excretion rate of Butabarbital which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Butriptyline. Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin. Canrenoic acid Canrenoic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine Goserelin may decrease the excretion rate of Capecitabine which could result in a higher serum level. Capreomycin Goserelin may decrease the excretion rate of Capreomycin which could result in a higher serum level. Capromab Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Capsaicin The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Capsaicin. Carbamazepine Goserelin may decrease the excretion rate of Carbamazepine which could result in a higher serum level. Carbidopa Goserelin may decrease the excretion rate of Carbidopa which could result in a higher serum level. Carbinoxamine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Carbinoxamine. Carboplatin Carboplatin may decrease the excretion rate of Goserelin which could result in a higher serum level. Carmustine Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level. Carprofen Carprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefaclor Cefaclor may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefdinir Goserelin may decrease the excretion rate of Cefdinir which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftaroline Ceftaroline fosamil may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceftolozane Goserelin may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Goserelin which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Goserelin which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Goserelin. Cephalexin Cephalexin may decrease the excretion rate of Goserelin which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Goserelin which could result in a higher serum level. Ceritinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib. Certolizumab pegol Goserelin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Goserelin. Cevimeline Goserelin may decrease the excretion rate of Cevimeline which could result in a higher serum level. Chloral hydrate Goserelin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Goserelin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chloroquine. Chlorothiazide Chlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Goserelin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpheniramine. Chlorpromazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpromazine. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Goserelin. Chlorthalidone Chlorthalidone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Goserelin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. Choline C 11 Goserelin may decrease effectiveness of Choline C 11 as a diagnostic agent. Choline magnesium Choline magnesium trisalicylate may decrease the excretion rate of Goserelin which could result in a higher serum level. Choline salicylate Goserelin may decrease the excretion rate of Choline salicylate which could result in a higher serum level. Chondroitin sulfate Goserelin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Goserelin may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Goserelin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Goserelin may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium Goserelin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Goserelin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Goserelin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Cidofovir Cidofovir may decrease the excretion rate of Goserelin which could result in a higher serum level. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Goserelin. Cimetidine Goserelin may decrease the excretion rate of Cimetidine which could result in a higher serum level. Cinchocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinnarizine. Cinoxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinoxacin. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cisapride. Cisplatin Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Citalopram The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram. Clarithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clemastine. Clevidipine Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level. Clobazam Goserelin may decrease the excretion rate of Clobazam which could result in a higher serum level. clofarabine Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Goserelin. Clomipramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clomipramine. Clonazepam Goserelin may decrease the excretion rate of Clonazepam which could result in a higher serum level. Clorazepic acid Goserelin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. Clove oil Goserelin may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cocaine. Colchicine Goserelin may decrease the excretion rate of Colchicine which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Goserelin which could result in a higher serum level. Colistin Goserelin may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Conjugated Goserelin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Corifollitropin The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Goserelin. Crizotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Crizotinib. Cyanocobalamin Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Goserelin. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Cyclosporine Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level. Cyclothiazide Cyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Goserelin. Dabigatran Goserelin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin. Dacarbazine Goserelin may decrease the excretion rate of Dacarbazine which could result in a higher serum level. Dalfampridine Goserelin may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin. Daptomycin Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin. Deferiprone Goserelin may decrease the excretion rate of Deferiprone which could result in a higher serum level. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Goserelin. Delamanid Goserelin may increase the QTc-prolonging activities of Delamanid. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Goserelin. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Goserelin. Desloratadine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Desloratadine. Desmopressin Goserelin may decrease the excretion rate of Desmopressin which could result in a higher serum level. Desvenlafaxine Goserelin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Deutetrabenazine. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin. Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine maleate. Dexibuprofen Dexibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Dexmedetomidine Goserelin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. Dexpanthenol Goserelin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Dextran Goserelin may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Goserelin may decrease the excretion rate of Diatrizoate which could result in a higher serum level. Diazepam Goserelin may decrease the excretion rate of Diazepam which could result in a higher serum level. Dichlorobenzyl Goserelin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac Diclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. Diclofenamide Diclofenamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Dicyclomine Goserelin may decrease the excretion rate of Dicyclomine which could result in a higher serum level. Didanosine Goserelin may decrease the excretion rate of Didanosine which could result in a higher serum level. Dienogest Goserelin may decrease the excretion rate of Dienogest which could result in a higher serum level. Diflunisal Diflunisal may decrease the excretion rate of Goserelin which could result in a higher serum level. Difluocortolone Goserelin may decrease the excretion rate of Difluocortolone which could result in a higher serum level. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Goserelin. Digoxin Goserelin may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Goserelin which could result in a higher serum level. Diltiazem The risk or severity of QTc prolongation can be increased when Goserelin is combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dimenhydrinate. Dimercaprol Goserelin may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl sulfoxide Goserelin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Goserelin. DL-Methylephedrine Goserelin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Goserelin may decrease the excretion rate of Dobutamine which could result in a higher serum level. Dofetilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron. Domperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone. Dopamine Goserelin may decrease the excretion rate of Dopamine which could result in a higher serum level. Doripenem Goserelin may decrease the excretion rate of Doripenem which could result in a higher serum level. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Goserelin. Doxacurium Goserelin may decrease the excretion rate of Doxacurium which could result in a higher serum level. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Goserelin. Doxycycline Goserelin may decrease the excretion rate of Doxycycline which could result in a higher serum level. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Goserelin. Dronedarone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Droperidol. Drospirenone Drospirenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Droxidopa Goserelin may decrease the excretion rate of Droxidopa which could result in a higher serum level. Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin. Duloxetine Goserelin may decrease the excretion rate of Duloxetine which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Dyclonine. Dyphylline Goserelin may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Goserelin. Edoxaban Goserelin may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Goserelin may decrease the excretion rate of Edrophonium which could result in a higher serum level. Efavirenz The risk or severity of QTc prolongation can be increased when Goserelin is combined with Efavirenz. Eliglustat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Eliglustat. Emedastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Emedastine. Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin. Enalaprilat Goserelin may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Goserelin. Encorafenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Goserelin. Entrectinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib. Enzalutamide Goserelin may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Goserelin. Eplerenone Eplerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol Goserelin may decrease the excretion rate of Epoprostenol which could result in a higher serum level. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Goserelin. Erlotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib. Ertapenem Goserelin may decrease the excretion rate of Ertapenem which could result in a higher serum level. Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Goserelin. Erythromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Goserelin. Escitalopram The risk or severity of QTc prolongation can be increased when Goserelin is combined with Escitalopram. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Goserelin. Estazolam Goserelin may decrease the excretion rate of Estazolam which could result in a higher serum level. Estradiol Goserelin may decrease the excretion rate of Estradiol which could result in a higher serum level. Estradiol acetate Goserelin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. Estradiol cypionate Goserelin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. Estradiol dienanthate Goserelin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. Estradiol valerate Goserelin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. Estrone sulfate Goserelin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. Eszopiclone Goserelin may decrease the excretion rate of Eszopiclone which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Goserelin may decrease the excretion rate of Etafedrine which could result in a higher serum level. Ethambutol Goserelin may decrease the excretion rate of Ethambutol which could result in a higher serum level. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Goserelin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Etidocaine. Etodolac Etodolac may decrease the excretion rate of Goserelin which could result in a higher serum level. Etomidate Goserelin may decrease the excretion rate of Etomidate which could result in a higher serum level. Etonogestrel Goserelin may decrease the excretion rate of Etonogestrel which could result in a higher serum level. Etoricoxib Etoricoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Eucalyptus oil Goserelin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Goserelin. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Goserelin. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Goserelin. Fenbufen Fenbufen may decrease the excretion rate of Goserelin which could result in a higher serum level. Fenofibrate Goserelin may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fenofibric acid Goserelin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Goserelin may decrease the excretion rate of Fenoldopam which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Fentanyl Goserelin may decrease the excretion rate of Fentanyl which could result in a higher serum level. Fesoterodine Goserelin may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Fexinidazole The risk or severity of adverse effects can be increased when Goserelin is combined with Fexinidazole. Finerenone Finerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Flavoxate Goserelin may decrease the excretion rate of Flavoxate which could result in a higher serum level. Flecainide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flecainide. Floctafenine Floctafenine may decrease the excretion rate of Goserelin which could result in a higher serum level. Florbetaben (18F) Goserelin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir (18F) Goserelin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine Goserelin may decrease the excretion rate of Floxuridine which could result in a higher serum level. Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Goserelin. Flucytosine Goserelin may decrease the excretion rate of Flucytosine which could result in a higher serum level. Fludeoxyglucose Goserelin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Flumazenil Goserelin may decrease the excretion rate of Flumazenil which could result in a higher serum level. Fluocinolone Goserelin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level. Fluorouracil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Goserelin. Flupentixol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flupentixol. Flurazepam Goserelin may decrease the excretion rate of Flurazepam which could result in a higher serum level. Flurbiprofen Flurbiprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Fluspirilene The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluspirilene. Flutamide Goserelin may decrease the excretion rate of Flutamide which could result in a higher serum level. Fluvoxamine Goserelin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. Folic acid Goserelin may decrease the excretion rate of Folic acid which could result in a higher serum level. Fomepizole Goserelin may decrease the excretion rate of Fomepizole which could result in a higher serum level. Fondaparinux Goserelin may decrease the excretion rate of Fondaparinux which could result in a higher serum level. Formestane Goserelin may decrease the excretion rate of Formestane which could result in a higher serum level. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Goserelin. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Goserelin. Fosfomycin Goserelin may decrease the excretion rate of Fosfomycin which could result in a higher serum level. Fosinopril Goserelin may decrease the excretion rate of Fosinopril which could result in a higher serum level. Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Goserelin. Framycetin Framycetin may decrease the excretion rate of Goserelin which could result in a higher serum level. Furosemide Furosemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Gabapentin Goserelin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gadobenic acid. Gadodiamide Goserelin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Gadofosveset Goserelin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Goserelin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Gadoteric acid Goserelin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Goserelin may decrease the excretion rate of Gadoteridol which could result in a higher serum level. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Goserelin. Ganciclovir Goserelin may decrease the excretion rate of Ganciclovir which could result in a higher serum level. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Goserelin. Gemcitabine Goserelin may decrease the excretion rate of Gemcitabine which could result in a higher serum level. Gemfibrozil Goserelin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level. Gemifloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gemifloxacin. Gentamicin Goserelin may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gilteritinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib. Gimeracil Goserelin may decrease the excretion rate of Gimeracil which could result in a higher serum level. Givosiran Givosiran may decrease the excretion rate of Goserelin which could result in a higher serum level. Glasdegib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib. Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin. Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin. Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin. Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin. Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin. Glycerol phenylbu Goserelin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Goserelin. Golodirsen Goserelin may decrease the excretion rate of Golodirsen which could result in a higher serum level. Granisetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Granisetron. Grepafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Grepafloxacin. Guanethidine Goserelin may decrease the excretion rate of Guanethidine which could result in a higher serum level. Guanfacine Goserelin may decrease the excretion rate of Guanfacine which could result in a higher serum level. Halofantrine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Goserelin. Hydralazine Goserelin may decrease the excretion rate of Hydralazine which could result in a higher serum level. Hydrochlorothiazide Hydrochlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Goserelin may decrease the excretion rate of Hydromorphone which could result in a higher serum level. Hydroxocobalamin Goserelin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Goserelin. Hydroxyethyl Starch Goserelin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Hydroxyzine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Goserelin. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin. Ibuprofen Ibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Ibutilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ibutilide. Icatibant Goserelin may decrease the excretion rate of Icatibant which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Goserelin which could result in a higher serum level. Idarucizumab Goserelin may decrease the excretion rate of Idarucizumab which could result in a higher serum level. Idebenone Goserelin may decrease the excretion rate of Idebenone which could result in a higher serum level. Ifosfamide Goserelin may decrease the excretion rate of Ifosfamide which could result in a higher serum level. Iloperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Iloperidone. Imatinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imatinib. Imipramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Goserelin. Indapamide Indapamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Indigotindisulfonic Goserelin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. Indomethacin Indomethacin may decrease the excretion rate of Goserelin which could result in a higher serum level. Inosine pranobex Goserelin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Inositol Goserelin may decrease the excretion rate of Inositol which could result in a higher serum level. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Goserelin. Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Goserelin. Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Goserelin. Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Goserelin. Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin. Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Goserelin. Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin. Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin. Iobenguane Goserelin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. Iodixanol Goserelin may decrease the excretion rate of Iodixanol which could result in a higher serum level. Ioflupane I-123 Goserelin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Iopromide Goserelin may decrease the excretion rate of Iopromide which could result in a higher serum level. Iothalamic acid Goserelin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Ioversol Goserelin may decrease the excretion rate of Ioversol which could result in a higher serum level. Ioxilan Goserelin may decrease the excretion rate of Ioxilan which could result in a higher serum level. Ipecac Goserelin may decrease the excretion rate of Ipecac which could result in a higher serum level. Ipilimumab Goserelin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Goserelin. Isoniazid Goserelin may decrease the excretion rate of Isoniazid which could result in a higher serum level. Isosorbide Isosorbide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Isosorbide Goserelin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. Isosulfan blue Goserelin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. Isotretinoin Goserelin may decrease the excretion rate of Isotretinoin which could result in a higher serum level. Isoxicam Isoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Goserelin. Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Goserelin. Ivabradine Ivabradine may increase the QTc-prolonging activities of Goserelin. Ivosidenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib. Ixazomib Goserelin may decrease the excretion rate of Ixazomib which could result in a higher serum level. Kanamycin Goserelin may decrease the excretion rate of Kanamycin which could result in a higher serum level. Ketamine Goserelin may decrease the excretion rate of Ketamine which could result in a higher serum level. Ketazolam Goserelin may decrease the excretion rate of Ketazolam which could result in a higher serum level. Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Goserelin. Ketoprofen Ketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Ketorolac Ketorolac may decrease the excretion rate of Goserelin which could result in a higher serum level. Labetalol Goserelin may decrease the excretion rate of Labetalol which could result in a higher serum level. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Goserelin. Lamivudine Goserelin may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Goserelin. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Goserelin. Latamoxef Latamoxef may decrease the excretion rate of Goserelin which could result in a higher serum level. Ledipasvir Goserelin may decrease the excretion rate of Ledipasvir which could result in a higher serum level. Lefamulin Lefamulin may increase the QTc-prolonging activities of Goserelin. Lenalidomide Goserelin may decrease the excretion rate of Lenalidomide which could result in a higher serum level. Lenvatinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lenvatinib. Lesinurad Goserelin may decrease the excretion rate of Lesinurad which could result in a higher serum level. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levacetylmethadol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Goserelin. Levocarnitine Goserelin may decrease the excretion rate of Levocarnitine which could result in a higher serum level. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Goserelin. Levofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Goserelin. Levomilnacipran Goserelin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. Levosalbutamol Goserelin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Levosimendan The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Goserelin. Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin. Liothyronine Goserelin may decrease the excretion rate of Liothyronine which could result in a higher serum level. Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin. Lisinopril Goserelin may decrease the excretion rate of Lisinopril which could result in a higher serum level. Lithium carbonate Goserelin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Goserelin which could result in a higher serum level. Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Goserelin. Lofexidine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lomefloxacin. Loperamide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Loperamide. Lopinavir The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Goserelin. Loracarbef Loracarbef may decrease the excretion rate of Goserelin which could result in a higher serum level. Lorazepam Goserelin may decrease the excretion rate of Lorazepam which could result in a higher serum level. Lorcaserin Goserelin may decrease the excretion rate of Lorcaserin which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. Lorpiprazole Goserelin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Goserelin. Loxoprofen Loxoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. Lubiprostone Goserelin may decrease the excretion rate of Lubiprostone which could result in a higher serum level. Lumefantrine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lumefantrine. Lumiracoxib Lumiracoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Goserelin. Macimorelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Macimorelin. Macitentan Goserelin may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium car Goserelin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chl Goserelin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium hydr Goserelin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium trisi Goserelin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Goserelin may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Mannitol Mannitol may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Goserelin. Mecamylamine Goserelin may decrease the excretion rate of Mecamylamine which could result in a higher serum level. Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Goserelin. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Medroxyprogester Goserelin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Goserelin. Megestrol acetate Goserelin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. Meloxicam The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Meloxicam. Memantine Goserelin may decrease the excretion rate of Memantine which could result in a higher serum level. Meperidine Goserelin may decrease the excretion rate of Meperidine which could result in a higher serum level. Mepivacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Mepivacaine. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Goserelin. Meropenem Goserelin may decrease the excretion rate of Meropenem which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. Mesoridazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mesoridazine. Metamfetamine Goserelin may decrease the excretion rate of Metamfetamine which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Goserelin which could result in a higher serum level. Metaxalone Goserelin may decrease the excretion rate of Metaxalone which could result in a higher serum level. Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin. Methadone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Methadone. Methazolamide Methazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Methimazole Goserelin may decrease the excretion rate of Methimazole which could result in a higher serum level. Methotrexate Methotrexate may decrease the excretion rate of Goserelin which could result in a higher serum level. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Goserelin. Methoxsalen Goserelin may decrease the excretion rate of Methoxsalen which could result in a higher serum level. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Goserelin. Methyldopa Goserelin may decrease the excretion rate of Methyldopa which could result in a higher serum level. Methylene blue Goserelin may decrease the excretion rate of Methylene blue which could result in a higher serum level. Methylnaltrexone Goserelin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. Methyltestosterone Goserelin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin. Metolazone Metolazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Goserelin may decrease the excretion rate of Metoprolol which could result in a higher serum level. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Goserelin. Metyrapone Goserelin may decrease the excretion rate of Metyrapone which could result in a higher serum level. Midazolam Goserelin may decrease the excretion rate of Midazolam which could result in a higher serum level. Mifepristone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mifepristone. Migalastat Goserelin may decrease the excretion rate of Migalastat which could result in a higher serum level. Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin. Milnacipran Goserelin may decrease the excretion rate of Milnacipran which could result in a higher serum level. Milrinone Goserelin may decrease the excretion rate of Milrinone which could result in a higher serum level. Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Goserelin. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Goserelin. Mizolastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mobocertinib. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Goserelin. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Goserelin. Moxifloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin. Moxisylyte Goserelin may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Muzolimine Muzolimine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Mycophenolate Goserelin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Mycophenolic acid Goserelin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. N-acetyltyrosine Goserelin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. Nabumetone Nabumetone may decrease the excretion rate of Goserelin which could result in a higher serum level. Nadolol Goserelin may decrease the excretion rate of Nadolol which could result in a higher serum level. Naldemedine Goserelin may decrease the excretion rate of Naldemedine which could result in a higher serum level. Nalidixic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nalidixic acid. Nalmefene Goserelin may decrease the excretion rate of Nalmefene which could result in a higher serum level. Naloxone Goserelin may decrease the excretion rate of Naloxone which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Goserelin which could result in a higher serum level. Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin. Nedaplatin Goserelin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Goserelin may decrease the excretion rate of Nedocromil which could result in a higher serum level. Nefazodone Goserelin may decrease the excretion rate of Nefazodone which could result in a higher serum level. Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Goserelin. Neomycin Goserelin may decrease the excretion rate of Neomycin which could result in a higher serum level. Netilmicin Goserelin may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Goserelin. Nicorandil Goserelin may decrease the excretion rate of Nicorandil which could result in a higher serum level. Nifedipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nifedipine. Nilotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilotinib. Nilutamide Goserelin may decrease the excretion rate of Nilutamide which could result in a higher serum level. Nilvadipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilvadipine. Nimesulide Nimesulide may decrease the excretion rate of Goserelin which could result in a higher serum level. Nimodipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nimodipine. Nisoldipine Goserelin may decrease the excretion rate of Nisoldipine which could result in a higher serum level. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Goserelin. Nitric Oxide Goserelin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. Nitrofurantoin Goserelin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nitroprusside Goserelin may decrease the excretion rate of Nitroprusside which could result in a higher serum level. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Goserelin. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Goserelin. Octinoxate Goserelin may decrease the excretion rate of Octinoxate which could result in a higher serum level. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin. Ofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ofloxacin. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Goserelin. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Goserelin. Olsalazine Olsalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. Ondansetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ondansetron. Opium Goserelin may decrease the excretion rate of Opium which could result in a higher serum level. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Goserelin. Oseltamivir Goserelin may decrease the excretion rate of Oseltamivir which could result in a higher serum level. Oxacillin Goserelin may decrease the excretion rate of Oxacillin which could result in a higher serum level. Oxaliplatin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin. Oxaprozin Oxaprozin may decrease the excretion rate of Goserelin which could result in a higher serum level. Oxatomide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxatomide. Oxazepam Goserelin may decrease the excretion rate of Oxazepam which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxetacaine. Oxybenzone Goserelin may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxybuprocaine. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level. Oxyquinoline Goserelin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin. Pacritinib The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Goserelin. Paliperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Paliperidone. Palonosetron Goserelin may decrease the excretion rate of Palonosetron which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Panobinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Panobinostat. Pantoprazole Goserelin may decrease the excretion rate of Pantoprazole which could result in a higher serum level. Papaverine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine. Parecoxib Parecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Paromomycin Paromomycin may decrease the excretion rate of Goserelin which could result in a higher serum level. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Goserelin. Patent Blue Goserelin may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Goserelin. Pegaptanib Goserelin may decrease the excretion rate of Pegaptanib which could result in a higher serum level. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Goserelin. Pemetrexed Goserelin may decrease the excretion rate of Pemetrexed which could result in a higher serum level. Penbutolol Goserelin may decrease the excretion rate of Penbutolol which could result in a higher serum level. Pentaerythritol Goserelin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. Pentamidine The therapeutic efficacy of Pentamidine can be decreased when used in combination with Goserelin. Pentastarch Goserelin may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Goserelin may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Goserelin may decrease the excretion rate of Pentobarbital which could result in a higher serum level. Pentostatin Goserelin may decrease the excretion rate of Pentostatin which could result in a higher serum level. Pentoxifylline Goserelin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. Perflutren The risk or severity of QTc prolongation can be increased when Goserelin is combined with Perflutren. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Goserelin. Perindopril Goserelin may decrease the excretion rate of Perindopril which could result in a higher serum level. Permethrin Goserelin may decrease the excretion rate of Permethrin which could result in a higher serum level. Phenazopyridine Phenazopyridine may decrease the excretion rate of Goserelin which could result in a higher serum level. Phenelzine Goserelin may decrease the excretion rate of Phenelzine which could result in a higher serum level. Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin. Phenol The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Phenol. Phentolamine Goserelin may decrease the excretion rate of Phentolamine which could result in a higher serum level. Phenylbutazone Phenylbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level. Pholcodine Goserelin may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Goserelin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Goserelin may decrease the excretion rate of Phylloquinone which could result in a higher serum level. Picosulfuric acid Goserelin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimozide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pimozide. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Goserelin. Pindolol Goserelin may decrease the excretion rate of Pindolol which could result in a higher serum level. Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin. Piperacillin Goserelin may decrease the excretion rate of Piperacillin which could result in a higher serum level. Piracetam Goserelin may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Piroxicam Piroxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. Pitolisant Goserelin may increase the QTc-prolonging activities of Pitolisant. Plazomicin Goserelin may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Goserelin may decrease the excretion rate of Plerixafor which could result in a higher serum level. Polythiazide Polythiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Goserelin. Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Goserelin. Potassium Potassium may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Goserelin may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium Goserelin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Potassium chloride Goserelin may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Goserelin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium Goserelin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Goserelin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Pralatrexate Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralidoxime Goserelin may decrease the excretion rate of Pralidoxime which could result in a higher serum level. Pramipexole Goserelin may decrease the excretion rate of Pramipexole which could result in a higher serum level. Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin. Pramocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Pramocaine. Prasugrel Goserelin may decrease the excretion rate of Prasugrel which could result in a higher serum level. Prednisone Goserelin may decrease the excretion rate of Prednisone which could result in a higher serum level. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Goserelin. Prenylamine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prenylamine. Prilocaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Primaquine. Probenecid Goserelin may decrease the excretion rate of Probenecid which could result in a higher serum level. Probucol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Probucol. Procainamide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Procaine. Procaine benz Goserelin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Prochlorperazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prochlorperazine. Promazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Promazine. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Goserelin. Propafenone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone. Propantheline Goserelin may decrease the excretion rate of Propantheline which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Proparacaine. Propiverine Goserelin may decrease the excretion rate of Propiverine which could result in a higher serum level. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Goserelin. Propoxycaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Propoxycaine. Propranolol Goserelin may decrease the excretion rate of Propranolol which could result in a higher serum level. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Goserelin. Prucalopride Goserelin may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Goserelin may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Goserelin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. Pyridoxine Goserelin may decrease the excretion rate of Pyridoxine which could result in a higher serum level. Pyrithione Goserelin may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quetiapine. Quinethazone Quinethazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Quinidine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinidine. Quinine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine. Rabeprazole Goserelin may decrease the excretion rate of Rabeprazole which could result in a higher serum level. Ramelteon Goserelin may decrease the excretion rate of Ramelteon which could result in a higher serum level. Ranitidine Goserelin may decrease the excretion rate of Ranitidine which could result in a higher serum level. Ranolazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ranolazine. Rasagiline Goserelin may decrease the excretion rate of Rasagiline which could result in a higher serum level. Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Goserelin. Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin. Reserpine Goserelin may decrease the excretion rate of Reserpine which could result in a higher serum level. Resorcinol Goserelin may decrease the excretion rate of Resorcinol which could result in a higher serum level. Ribavirin Goserelin may decrease the excretion rate of Ribavirin which could result in a higher serum level. Ribociclib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ribociclib. Ribostamycin Goserelin may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Goserelin. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Goserelin. Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Goserelin. Rivaroxaban Goserelin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Goserelin may decrease the excretion rate of Rizatriptan which could result in a higher serum level. Rofecoxib Rofecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Roflumilast Goserelin may decrease the excretion rate of Roflumilast which could result in a higher serum level. Romidepsin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin. Ropivacaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ropivacaine. Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Goserelin. Roxithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Roxithromycin. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Goserelin. Ruxolitinib Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. Sacubitril Goserelin may decrease the excretion rate of Sacubitril which could result in a higher serum level. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Goserelin. Salicylamide Salicylamide may decrease the excretion rate of Goserelin which could result in a higher serum level. Salicylic acid Salicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin. Salmon calcitonin Goserelin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Goserelin which could result in a higher serum level. Saquinavir The risk or severity of QTc prolongation can be increased when Goserelin is combined with Saquinavir. Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin. Secobarbital Goserelin may decrease the excretion rate of Secobarbital which could result in a higher serum level. Selenious acid Goserelin may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Goserelin may decrease the excretion rate of Selenium which could result in a higher serum level. Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Goserelin. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Goserelin. Sibutramine Goserelin may decrease the excretion rate of Sibutramine which could result in a higher serum level. Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin. Sodium acetate Goserelin may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium auro Goserelin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium fluoride Goserelin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Goserelin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Goserelin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Goserelin. Solriamfetol Goserelin may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Goserelin. Sorbitol Goserelin may decrease the excretion rate of Sorbitol which could result in a higher serum level. Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin. Sotalol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol. Sparfloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sparfloxacin. Spironolactone Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol Goserelin may decrease the excretion rate of Stiripentol which could result in a higher serum level. Streptomycin Goserelin may decrease the excretion rate of Streptomycin which could result in a higher serum level. Strontium chloride Goserelin may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Goserelin may decrease the excretion rate of Sucralfate which could result in a higher serum level. Sulbactam Goserelin may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Goserelin. Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Goserelin. Sulfasalazine Sulfasalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Goserelin. Sulindac Sulindac may decrease the excretion rate of Goserelin which could result in a higher serum level. Sulpiride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sulpiride. Sultopride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sultopride. Sumatriptan Goserelin may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The therapeutic efficacy of Sunitinib can be decreased when used in combination with Goserelin. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Goserelin. Tadalafil Goserelin may decrease the excretion rate of Tadalafil which could result in a higher serum level. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Goserelin. Tamsulosin Goserelin may decrease the excretion rate of Tamsulosin which could result in a higher serum level. Tasimelteon Goserelin may decrease the excretion rate of Tasimelteon which could result in a higher serum level. Technetium T Goserelin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. Technetium Goserelin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. Technetium Goserelin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. Technetium Tc Goserelin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Teduglutide Goserelin may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Goserelin may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telavancin. Telithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telithromycin. Temazepam Goserelin may decrease the excretion rate of Temazepam which could result in a higher serum level. Temozolomide Goserelin may decrease the excretion rate of Temozolomide which could result in a higher serum level. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Goserelin. Tenofovir Tenofovir disoproxil may decrease the excretion rate of Goserelin which could result in a higher serum level. Tenoxicam Tenoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Goserelin. Terfenadine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terfenadine. Terlipressin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terlipressin. Testolactone Goserelin may decrease the excretion rate of Testolactone which could result in a higher serum level. Testosterone Goserelin may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Goserelin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Goserelin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone pro Goserelin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. Testosterone undec Goserelin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetrabenazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Tetracaine. Tetracycline Goserelin may decrease the excretion rate of Tetracycline which could result in a higher serum level. Tetradecyl Goserelin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Thiabendazole Goserelin may decrease the excretion rate of Thiabendazole which could result in a higher serum level. Thiethylperazine Goserelin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. Thioridazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Thioridazine. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Goserelin. Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Ticlopidine Goserelin may decrease the excretion rate of Ticlopidine which could result in a higher serum level. Tiludronic acid Goserelin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Goserelin. Tinidazole Goserelin may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tiopronin Goserelin may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Goserelin may decrease the excretion rate of Tiotropium which could result in a higher serum level. Tirofiban Goserelin may decrease the excretion rate of Tirofiban which could result in a higher serum level. Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Goserelin. Tixocortol Goserelin may decrease the excretion rate of Tixocortol which could result in a higher serum level. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Goserelin. Tobramycin Goserelin may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tocopherol Goserelin may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin. Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin. Tolcapone Goserelin may decrease the excretion rate of Tolcapone which could result in a higher serum level. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Goserelin which could result in a higher serum level. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Goserelin. Tolvaptan Tolvaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Goserelin may decrease the excretion rate of Topiramate which could result in a higher serum level. Topotecan Goserelin may decrease the excretion rate of Topotecan which could result in a higher serum level. Torasemide Torasemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Toremifene The risk or severity of QTc prolongation can be increased when Goserelin is combined with Toremifene. Tositumomab Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level. Tramadol Goserelin may decrease the excretion rate of Tramadol which could result in a higher serum level. Trametinib Goserelin may decrease the excretion rate of Trametinib which could result in a higher serum level. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Goserelin. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Goserelin. Triamterene Triamterene may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Goserelin may decrease the excretion rate of Triazolam which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Goserelin. Triethylenetetram Goserelin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. Trifluridine Goserelin may decrease the excretion rate of Trifluridine which could result in a higher serum level. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Goserelin. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Goserelin. Trimethoprim Goserelin may decrease the excretion rate of Trimethoprim which could result in a higher serum level. Trimetrexate Goserelin may decrease the excretion rate of Trimetrexate which could result in a higher serum level. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Goserelin. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Goserelin. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin. Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin. Tropisetron Goserelin may decrease the excretion rate of Tropisetron which could result in a higher serum level. Trovafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Trovafloxacin. Vaborbactam Goserelin may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Goserelin which could result in a higher serum level. Valbenazine Goserelin may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. Valganciclovir Goserelin may decrease the excretion rate of Valganciclovir which could result in a higher serum level. Valproic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid. Vancomycin Goserelin may decrease the excretion rate of Vancomycin which could result in a higher serum level. Vandetanib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vandetanib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Goserelin. Varenicline Goserelin may decrease the excretion rate of Varenicline which could result in a higher serum level. Vemurafenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vemurafenib. Venlafaxine Goserelin may decrease the excretion rate of Venlafaxine which could result in a higher serum level. Verapamil Goserelin may decrease the excretion rate of Verapamil which could result in a higher serum level. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Goserelin. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Goserelin. Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin. Viloxazine Goserelin may decrease the excretion rate of Viloxazine which could result in a higher serum level. Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Goserelin. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Goserelin. Vortioxetine Goserelin may decrease the excretion rate of Vortioxetine which could result in a higher serum level. Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Pregnancy This drug is contraindicated during pregnancy unless it is being used for the palliative treatment of advanced breast cancer. This drug can harm a developing fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. There is an increased risk of pregnancy loss due to hormone changes caused by this drug. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. Lactation A decision should be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother; some experts consider use to be contraindicated. How should this medicine be used? Goserelin comes as an implant to be inserted with a syringe subcutaneously (under the skin) in your stomach area by a doctor or nurse in a medical office or clinic. An implant with 3.6 mg of goserelin is usually inserted every 4 weeks. An implant with 10.8 mg of goserelin is usually inserted every 12 weeks. The length of your treatment depends on the condition being treated and your response to the medication. Your doctor will determine how long you should use the goserelin implant. Goserelin may cause an increase in certain hormones in the first few weeks after insertion of the implant. Your doctor will monitor you carefully for any new or worsening symptoms during this time. What special precautions should I follow? Before receiving a goserelin implant, tell your doctor and pharmacist if you are allergic to goserelin, histrelin (Supprelin LA, Vantas), leuprolide (Eligard, Lupron), nafarelin (Synarel), triptorelin (Trelstar), any other medications, or any of the ingredients in goserelin implant. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: medications for seizures or oral steroids such as dexamethasone (Decadron, Dexpak), methylprednisolone (Medrol), and prednisone (Sterapred). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have a history of drinking alcohol or using tobacco products for a long period of time, or if you or anyone in your family has or has ever had osteoporosis (a condition in which the bones become thin and weak and break easily), or if you have or have ever had a compressed spinal cord, diabetes, unusual vaginal bleeding, urinary obstruction in men (blockage that causes difficulty urinating), or heart or liver disease. tell your doctor if you are pregnant or plan to become pregnant. Goserelin implants should not be used in pregnant women, except for the treatment of advanced breast cancer. Call your doctor right away if you think you have become pregnant during your treatment. Goserelin implant may harm the fetus. You should not plan to become pregnant while using a goserelin implant or for 12 weeks after your treatment. Your doctor may perform a pregnancy test or tell you to begin your treatment during your menstrual period to be sure that you are not pregnant when you begin using the goserelin implant. You will need to use a reliable nonhormonal method of birth control to prevent pregnancy while you are using a goserelin implant and for 12 weeks after your treatment. Talk to your doctor about the types of birth control that are right for you, and continue to use birth control even though you should not have regular menstrual periods during your treatment. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with a goserelin implant. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019726s050s051s052lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020578s034,020578s035lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/psg/Goserelin_Acetate_impSQ_20578_19726_RC10-08.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Goserelin https://pubchem.ncbi.nlm.nih.gov/compound/Fertilan https://www.drugs.com/zoladex.html https://go.drugbank.com/drugs/DB00014 https://medlineplus.gov/druginfo/meds/a601002.html https://en.wikipedia.org/wiki/Goserelin https://www.mayoclinic.org/drugs-supplements/goserelin-subcutaneous-route/side-effects/drg-20067310 https://www.webmd.com/drugs/2/drug-7104/goserelin-subcutaneous/details/list-contraindications http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5523 http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology DrugBank https://www.drugbank.ca/legal/terms_of_use Goserelin https://www.drugbank.ca/drugs/DB00014 FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking GOSERELIN https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox https://www.nlm.nih.gov/copyright.html Goserelin https://www.ncbi.nlm.nih.gov/books/n/livertox/Goserelin/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1374 NCI Thesaurus Tree https://ncit.nci.nih.gov ChemIDplus https://www.nlm.nih.gov/copyright.html https://chem.nlm.nih.gov/chemidplus/sid/0065807025 https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Goserelin https://comptox.epa.gov/dashboard/DTXSID7048297 https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/217097 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking GOSERELIN https://gsrs.ncats.nih.gov/ginas/app/beta/substances/0F65R8P09N Hazardous Substances Data Bank (HSDB) GOSERELIN https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7606 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Goserelin http://www.hmdb.ca/metabolites/HMDB0014259 https://hmdb.ca/metabolites/HMDB0014259#spectra ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp Goserelin https://ctdbase.org/detail.go?type=chem&acc=D017273 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads GOSERELIN https://www.dgidb.org/drugs/GOSERELIN IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license goserelin https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3879 https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Goserelin http://idrblab.net/ttd/data/drug/details/D00BCG Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking goserelin https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking Patent:7118552 https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking GOSERELIN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory MassBank of North America (MoNA) https://mona.fiehnlab.ucdavis.edu/documentation/license Goserelin https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22BLCLNMBMMGCOAS-URPVMXJPSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Goserelin Acetate https://www.cancer.gov/about-cancer/treatment/drugs/goserelinacetate NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html goserelin https://rxnav.nlm.nih.gov/id/rxnorm/50610 NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ PubChem https://pubchem.ncbi.nlm.nih.gov Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=91078963-708125756 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=91078963-708262516 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Goserelin https://list.essentialmeds.org/medicines/873 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Goserelin https://www.wikidata.org/wiki/Q1992653 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Goserelin https://www.ncbi.nlm.nih.gov/mesh/68017273 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents, Hormonal https://www.ncbi.nlm.nih.gov/mesh/68018931 KEGG https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 403598084 https://pubchem.ncbi.nlm.nih.gov/substance/403598084 Show More